E
BIOC

Ergoteles’s Biocept, Inc. BIOC Stock Holding History

Ergoteles’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-734
Closed -$7.49K – 1713
2023
Q1 		$7.49K Buy
+734
New +$10.6K ﹤0.01% 1178

Other funds holding BIOC

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ergoteles's BIOC Position: Q2 2023 in Review

Ergoteles sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 734 shares — an estimated $7.49K sold.

Ergoteles first reported a position in BIOC in Q1 2023 and held it in 1 quarter. The position peaked at $7.49K in Q1 2023. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

  • Ergoteles reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 734 Biocept, Inc. shares in Q2 2023, an estimated $7.49K.
  • Ergoteles first reported a position in Biocept, Inc. in Q1 2023 and held it in 1 quarter.
  • Ergoteles's Biocept, Inc. position peaked at $7.49K in Q1 2023.
  • 11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.